Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

499
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
499
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

962
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
962
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

1.2K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.2K
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.0K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.0K
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

795
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
795
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

477
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
477

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE Study.

Advances in therapy·2026
Same author

Virtual chromoendoscopy with linked color imaging versus dye-chromoendoscopy in the surveillance of patients with long-standing colonic inflammatory bowel disease.

Journal of Crohn's & colitis·2026
Same author

Corrigendum to 'Dynamic profiling in inflammatory Bowel disease: A manifesto for personalized care' [Autoimmunity Reviews 25 (2026) 104068].

Autoimmunity reviews·2026
Same author

Vedolizumab for the prevention and treatment of postoperative recurrence in Crohn's disease: A real- world latium net study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same author

Dynamic profiling in inflammatory Bowel disease: A manifesto for personalized care.

Autoimmunity reviews·2026
Same author

Sustainable monitoring in inflammatory bowel disease: comparative carbon, energy, waste, and cost impact of intestinal ultrasound versus colonoscopy.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same journal

Evidence-Based Clinical Recommendations for the Appropriate Use of Diagnostic Tests in Pediatric Allergology: Focus on Asthma, Rhinoconjunctivitis, and Keratoconjunctivitis Vernal.

Journal of clinical medicine·2026
Same journal

Surgical and Transcatheter Approach of a Failed Mitral Valve Repair: A Comprehensive Review on Selecting the Most Suitable Approach.

Journal of clinical medicine·2026
Same journal

Hybrid Metaheuristic Feature Selection for Breast Cancer Detection in Digital Mammography: A Feasibility Study with Nested Validation, Benchmarking, and External Stress Testing.

Journal of clinical medicine·2026
Same journal

Identity Transformation and the Role of Accountability in Recovery from Problematic Pornography Use: A Phenomenological-Hermeneutical Study.

Journal of clinical medicine·2026
Same journal

Does Early Surgical Treatment in Degenerative Cervical Myelopathy Have a Favorable Clinical Outcome and Impact on Quality of Life?

Journal of clinical medicine·2026
Same journal

Shear Wave Elastography in Musculoskeletal Imaging: A Narrative Review.

Journal of clinical medicine·2026
See all related articles

Related Experiment Video

Updated: Jan 29, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.5K

Treat-to-Target in Ulcerative Colitis: How Soon Is Now?

Laura Parisio1, Giuseppe Cuccia1, Giuseppe Privitera2

  • 1UOS Gastroenterologia, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy.

Journal of Clinical Medicine
|January 28, 2026
PubMed
Summary
This summary is machine-generated.

Treat-to-target strategies aim for complete disease control in ulcerative colitis (UC) by monitoring inflammation and escalating therapy. Current evidence shows many UC patients remain uncontrolled, highlighting the need for improved management approaches.

Keywords:
biomarkersendoscopytreat-to-targetulcerative colitisultrasound

More Related Videos

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

3.7K
Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.6K

Related Experiment Videos

Last Updated: Jan 29, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.5K
Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

3.7K
Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.6K

Area of Science:

  • Gastroenterology
  • Inflammatory Bowel Disease Research
  • Clinical Therapeutics

Background:

  • Ulcerative colitis (UC) is a progressive inflammatory bowel disease requiring advanced management beyond symptom control.
  • Therapeutic goals have shifted towards achieving remission (endoscopic, histologic) for better long-term outcomes.
  • Disease clearance, encompassing clinical, endoscopic, and histologic healing, is the proposed ultimate treatment target for UC.

Purpose of the Study:

  • To explore the current evidence and future directions for treat-to-target strategies in ulcerative colitis (UC) management.
  • To assess the implementation and effectiveness of treat-to-target approaches in routine clinical practice for UC.
  • To identify challenges and unmet needs in achieving complete disease control for UC patients.

Main Methods:

  • Review of current literature on treat-to-target strategies in UC.
  • Analysis of recent real-life data on UC patient control according to STRIDE II criteria.
  • Discussion of evidence supporting and limiting the application of treat-to-target approaches in UC.

Main Results:

  • A treat-to-target approach, like STRIDE II, is proposed for UC but lacks robust evidence compared to Crohn's disease.
  • Nearly half of UC patients are inadequately controlled by current therapies based on STRIDE II criteria.
  • Reasons for inadequate control include steroid overuse, persistent inflammation, extra-intestinal manifestations, and reduced quality of life.

Conclusions:

  • Treat-to-target strategies are crucial for optimizing ulcerative colitis management and achieving stringent outcomes.
  • Further research and clinical validation are needed to refine and implement these strategies effectively in UC.
  • Addressing barriers to effective UC treatment is essential for improving patient outcomes and quality of life.